Pharvaris (PHVS) N.V. announced that it intends to offer and sell $150M of ordinary shares in an underwritten public offering. All shares in the offering are to be sold by Pharvaris. Pharvaris currently intends to use the net proceeds of this offering primarily to fund research and development expenses for its late-stage clinical programs, the hiring of a sales and marketing team in the U.S. and related commercialization expenses and for working capital and general corporate purposes. Morgan Stanley, Leerink Partners, Cantor, Oppenheimer & Co., and Van Lanschot Kempen are acting as joint book-running managers.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHVS:
- Pharvaris’s Accelerated Phase 3 Trial Timeline and Market Potential Boost Buy Rating
- Pharvaris’s Promising Outlook: Accelerated Timeline and Market Potential for Deucrictibant in HAE Treatment
- Pharvaris Updates RAPIDe-3 Study Timeline for HAE Treatment
- Pharvaris to report topline Phase 3 results of deucrictibant in Q4
- Pharvaris Announces Key Resolutions from Annual General Meeting